Clinical Trial

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
When bladder cancer patients are treated to mobilize their own immune system to fight the tumor, drugs that kill the bacteria can impair the effectiveness of the treatment. The purpose of this study is to find out if the common dietary supplement Vitamin B3 could allow drugs that kill bacteria to not negatively affect treatments that mobilize the immune system to fight tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-06.
Status change: Not Yet Recruiting → Recruiting 2026-06-28
Trial Details
NCT Number NCT07119996
Lead Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions Bladder (Urothelial, Transitional Cell) Cancer
Enrollment 12 participants
Start Date 2025-08-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-30